AR045093A1 - Composición farmacéutica y uso de antibióticos de quinolona - Google Patents
Composición farmacéutica y uso de antibióticos de quinolonaInfo
- Publication number
- AR045093A1 AR045093A1 ARP040102624A ARP040102624A AR045093A1 AR 045093 A1 AR045093 A1 AR 045093A1 AR P040102624 A ARP040102624 A AR P040102624A AR P040102624 A ARP040102624 A AR P040102624A AR 045093 A1 AR045093 A1 AR 045093A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cyano
- methoxy
- quinolone antibiotics
- antibiotics
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title abstract 5
- 229940088710 antibiotic agent Drugs 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- -1 marboflioxacin Chemical compound 0.000 abstract 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- VTAJXTQJNZWWGT-UHFFFAOYSA-N 2-oxo-1h-quinoline-8-carbonitrile Chemical compound C1=CC(C#N)=C2NC(=O)C=CC2=C1 VTAJXTQJNZWWGT-UHFFFAOYSA-N 0.000 abstract 3
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 210000000214 mouth Anatomy 0.000 abstract 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 abstract 1
- QMLVECGLEOSESV-RYUDHWBXSA-N Danofloxacin Chemical compound C([C@@H]1C[C@H]2CN1C)N2C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=CC=1N2C1CC1 QMLVECGLEOSESV-RYUDHWBXSA-N 0.000 abstract 1
- QIPQASLPWJVQMH-DTORHVGOSA-N Orbifloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(F)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F QIPQASLPWJVQMH-DTORHVGOSA-N 0.000 abstract 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 abstract 1
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 229960004385 danofloxacin Drugs 0.000 abstract 1
- 229950001733 difloxacin Drugs 0.000 abstract 1
- NOCJXYPHIIZEHN-UHFFFAOYSA-N difloxacin Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1 NOCJXYPHIIZEHN-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- NJDRXTDGYFKORP-LLVKDONJSA-N garenoxacin Chemical compound N([C@@H](C1=CC=2)C)CC1=CC=2C(C=1OC(F)F)=CC=C(C(C(C(O)=O)=C2)=O)C=1N2C1CC1 NJDRXTDGYFKORP-LLVKDONJSA-N 0.000 abstract 1
- 229960001430 garenoxacin Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229950007954 ibafloxacin Drugs 0.000 abstract 1
- DXKRGNXUIRKXNR-UHFFFAOYSA-N ibafloxacin Chemical compound C1CC(C)N2C=C(C(O)=O)C(=O)C3=C2C1=C(C)C(F)=C3 DXKRGNXUIRKXNR-UHFFFAOYSA-N 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 abstract 1
- 229960004780 orbifloxacin Drugs 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229960001248 pradofloxacin Drugs 0.000 abstract 1
- LZLXHGFNOWILIY-APPDUMDISA-N pradofloxacin Chemical compound C12=C(C#N)C(N3C[C@H]4NCCC[C@H]4C3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 LZLXHGFNOWILIY-APPDUMDISA-N 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 239000003306 quinoline derived antiinfective agent Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
Uso de determinados antibióticos de quinolona para la lucha contra las enfermedades bacterianas de la cavidad bucal, especialmente en la medicina veterinaria. Reivindicación 1: Una composición farmacéutica para el tratamiento sistémico de enfermedades bacterianas en la cavidad bucal que comprende: a) antibióticos de 8-ciano-quinolona o b) antibióticos de quinolona elegidos del grupo formado por: garenoxacina, marboflioxacina, ibafloxacina, danofloxacina, difloxacina y orbifloxacina. Reivindicación 2: Una composición según la reivindicación 1, que comprende antibióticos de 8-ciano-quinolona de la fórmula (1) en la que X significa H, halógeno, alquilo C1-4, alcoxi C1-4, NH2, Y significa restos como se muestra en las estructuras (2) donde R4 significa alquilo C1-4 de cadena lineal o de cadena ramificada sustituido, en caso dado, por hidroxi o por metoxi, ciclopropilo, acilo C1-3, R5 significa H, metilo, fenilo, tienilo o piridilo; R6 significa H o alquilo C1-4; R7 significa H o alquilo C1-4; R8 significa H o alquilo C1-4; así como R1 significa un resto alquilo C1-3, ciclopropilo, 2-flúoretilo, metoxi, 4-flúorfenilo, 2,4-diflúorfenilo o metilamino; R2 significa H o alquilo C1-6 sustituido, en caso dado, por metoxi o por 2-metoxietoxi así como ciclohexilo, bencilo, 2-oxopropilo, fenacilo, etoxicarbonilmetilo, pivaloiloximetilo; A significa =C(CN); y sus sales e hidratos farmacéuticamente empleables. Reivindicación 3 Una composición según la reivindicación 1, en el que el antibiótico de 8-ciano-quinolona es la pradofloxacina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10337191A DE10337191A1 (de) | 2003-08-13 | 2003-08-13 | Neue Verwendung von Chinolon-Antibiotika |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045093A1 true AR045093A1 (es) | 2005-10-12 |
Family
ID=34201505
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102624A AR045093A1 (es) | 2003-08-13 | 2004-07-23 | Composición farmacéutica y uso de antibióticos de quinolona |
| ARP170102528A AR109644A2 (es) | 2003-08-13 | 2017-09-13 | Pradofloxacina y composición farmacéutica para el tratamiento sistémico de enfermedades bacterianas en la cavidad bucal |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102528A AR109644A2 (es) | 2003-08-13 | 2017-09-13 | Pradofloxacina y composición farmacéutica para el tratamiento sistémico de enfermedades bacterianas en la cavidad bucal |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US8658645B2 (es) |
| EP (1) | EP1656143B1 (es) |
| JP (2) | JP5122814B2 (es) |
| KR (1) | KR101209119B1 (es) |
| CN (1) | CN100571702C (es) |
| AR (2) | AR045093A1 (es) |
| AT (1) | ATE528004T1 (es) |
| AU (2) | AU2004266452A1 (es) |
| BR (1) | BRPI0413509A (es) |
| CA (1) | CA2535637C (es) |
| CY (1) | CY1112167T1 (es) |
| DE (1) | DE10337191A1 (es) |
| DK (1) | DK1656143T3 (es) |
| ES (1) | ES2374728T3 (es) |
| GT (1) | GT200400156A (es) |
| HR (1) | HRP20120019T1 (es) |
| IL (1) | IL173655A (es) |
| LU (1) | LU91883I2 (es) |
| MX (1) | MXPA06001597A (es) |
| MY (1) | MY162652A (es) |
| NO (1) | NO333116B1 (es) |
| NZ (1) | NZ545261A (es) |
| PE (1) | PE20050341A1 (es) |
| PL (1) | PL1656143T3 (es) |
| PT (1) | PT1656143E (es) |
| RU (1) | RU2367437C2 (es) |
| SI (1) | SI1656143T1 (es) |
| TW (1) | TWI367095B (es) |
| UA (1) | UA85685C2 (es) |
| UY (1) | UY28465A1 (es) |
| WO (1) | WO2005018641A2 (es) |
| ZA (1) | ZA200601167B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200510425A (en) * | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| DE10337191A1 (de) * | 2003-08-13 | 2005-03-17 | Bayer Healthcare Ag | Neue Verwendung von Chinolon-Antibiotika |
| FR2896416B1 (fr) * | 2006-01-24 | 2010-08-13 | Vetoquinol | Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine |
| DE102006010643A1 (de) * | 2006-03-08 | 2007-09-13 | Bayer Healthcare Aktiengesellschaft | Arzneimittel enthaltend Fluorchinolone |
| DE102006049520A1 (de) | 2006-10-20 | 2008-04-24 | Bayer Healthcare Ag | Verfahren zur Herstellung von Pradofloxacin |
| DE102007055341A1 (de) * | 2007-11-19 | 2009-05-20 | Bayer Animal Health Gmbh | Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren |
| WO2010069493A1 (de) * | 2008-12-18 | 2010-06-24 | Bayer Animal Health Gmbh | Verbesserte wirkstoffkombination enthaltend ein antibiotikum und einen nichtsteroidalen entzündungshemmer (nsaid) |
| CN102988280B (zh) * | 2012-10-08 | 2014-03-19 | 新乡医学院 | 一种加雷沙星滴眼剂 |
| JP6358868B2 (ja) * | 2014-06-17 | 2018-07-18 | Ｄｓファーマアニマルヘルス株式会社 | オルビフロキサシンを含有する製剤組成物 |
| CN106831795B (zh) * | 2017-01-16 | 2018-12-21 | 石家庄学院 | 喹诺酮异土木香内酯衍生物及其制备和应用 |
| AU2019260015C1 (en) | 2018-04-25 | 2024-11-21 | Elanco Animal Health Gmbh | Process for the hydrolysis of quinolone carboxylic esters |
| MX2022006466A (es) | 2019-11-28 | 2022-08-17 | Bayer Ag | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmune. |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62205060A (ja) * | 1986-03-04 | 1987-09-09 | Kyorin Pharmaceut Co Ltd | ８位置換キノロンカルボン酸誘導体 |
| DE3702393A1 (de) * | 1987-01-28 | 1988-08-11 | Bayer Ag | 8-cyano-1-cyclopropyl-1,4-dihydro-4-oxo- 3-chinolincarbonsaeuren, verfahren zu ihrer herstellung und diese enthaltende antibakterielle mittel |
| KR100276477B1 (ko) * | 1996-02-09 | 2000-12-15 | 나카노 가쓰히코 | 퀴놀론카복실산유도체또는그의염 |
| HU228036B1 (en) * | 1996-02-23 | 2012-08-28 | Bayer Animal Health Gmbh | Optionally substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-[4,3,0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives, process producing them and medicaments thereof |
| TW415943B (en) * | 1996-06-28 | 2000-12-21 | Bayer Ag | 7-(3-vinyl-1,4-piperazin-1-yl)-substituted quinolonecarboxylic acids |
| DE19633480A1 (de) * | 1996-08-20 | 1998-02-26 | Bayer Ag | Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren |
| DE19652219A1 (de) * | 1996-12-16 | 1998-06-18 | Bayer Ag | Verwendung von 7-(1-Aminomethyl-2-oxa-7-azabicyclo[3.3.0]oct-7-yl)-chinolon- und naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen |
| WO1999010351A1 (en) * | 1997-08-22 | 1999-03-04 | Dainippon Pharmaceutical Co., Ltd. | Pyridonecarboxylic acid derivatives and intermediates for the preparation thereof |
| BR9915208A (pt) * | 1998-11-10 | 2001-07-31 | Bayer Ag | Preparado farmacêutico de moxifloxacina |
| DE19962470A1 (de) * | 1999-12-22 | 2001-07-12 | Schulz Hans Herrmann | Verwendung von Chemotherapeutika |
| DE10337191A1 (de) * | 2003-08-13 | 2005-03-17 | Bayer Healthcare Ag | Neue Verwendung von Chinolon-Antibiotika |
-
2003
- 2003-08-13 DE DE10337191A patent/DE10337191A1/de not_active Withdrawn
-
2004
- 2004-07-23 AR ARP040102624A patent/AR045093A1/es not_active Application Discontinuation
- 2004-08-02 UA UAA200602704A patent/UA85685C2/ru unknown
- 2004-08-02 MX MXPA06001597A patent/MXPA06001597A/es active IP Right Grant
- 2004-08-02 BR BRPI0413509-1A patent/BRPI0413509A/pt not_active Application Discontinuation
- 2004-08-02 CA CA2535637A patent/CA2535637C/en not_active Expired - Lifetime
- 2004-08-02 JP JP2006522943A patent/JP5122814B2/ja not_active Expired - Lifetime
- 2004-08-02 HR HR20120019T patent/HRP20120019T1/hr unknown
- 2004-08-02 PT PT04763700T patent/PT1656143E/pt unknown
- 2004-08-02 RU RU2006107497/15A patent/RU2367437C2/ru active
- 2004-08-02 AU AU2004266452A patent/AU2004266452A1/en not_active Abandoned
- 2004-08-02 PL PL04763700T patent/PL1656143T3/pl unknown
- 2004-08-02 ES ES04763700T patent/ES2374728T3/es not_active Expired - Lifetime
- 2004-08-02 WO PCT/EP2004/008629 patent/WO2005018641A2/de not_active Ceased
- 2004-08-02 KR KR1020067002816A patent/KR101209119B1/ko not_active Expired - Lifetime
- 2004-08-02 DK DK04763700.4T patent/DK1656143T3/da active
- 2004-08-02 SI SI200431807T patent/SI1656143T1/sl unknown
- 2004-08-02 US US10/567,057 patent/US8658645B2/en active Active
- 2004-08-02 AT AT04763700T patent/ATE528004T1/de active
- 2004-08-02 NZ NZ545261A patent/NZ545261A/en not_active IP Right Cessation
- 2004-08-02 CN CNB2004800299003A patent/CN100571702C/zh not_active Expired - Lifetime
- 2004-08-02 EP EP04763700A patent/EP1656143B1/de not_active Expired - Lifetime
- 2004-08-11 UY UY28465A patent/UY28465A1/es not_active Application Discontinuation
- 2004-08-11 PE PE2004000780A patent/PE20050341A1/es not_active Application Discontinuation
- 2004-08-11 MY MYPI20043261A patent/MY162652A/en unknown
- 2004-08-11 GT GT200400156A patent/GT200400156A/es unknown
- 2004-08-12 TW TW093124130A patent/TWI367095B/zh not_active IP Right Cessation
-
2006
- 2006-02-09 ZA ZA200601167A patent/ZA200601167B/en unknown
- 2006-02-09 IL IL173655A patent/IL173655A/en active IP Right Grant
- 2006-03-08 NO NO20061127A patent/NO333116B1/no unknown
-
2011
- 2011-01-28 AU AU2011200356A patent/AU2011200356B2/en not_active Expired
- 2011-10-12 LU LU91883C patent/LU91883I2/fr unknown
- 2011-12-16 CY CY20111101253T patent/CY1112167T1/el unknown
-
2012
- 2012-06-27 JP JP2012144576A patent/JP2012211170A/ja active Pending
-
2017
- 2017-09-13 AR ARP170102528A patent/AR109644A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045093A1 (es) | Composición farmacéutica y uso de antibióticos de quinolona | |
| DK2314582T3 (da) | Heterocykliske forbindelser som antivirusmidler | |
| HRP20090459T1 (hr) | Aminofenil derivati kao novi inhibitori histonskih deacetilaza | |
| CY1114861T1 (el) | Παραγωγα 3-αρυλαμινοπυριδινης | |
| CY1112232T1 (el) | Κινολινικα παραγωγα ως αναστολεις φωσφοδιεστερασης | |
| CY1113846T1 (el) | Παραγωγα πυριμιδινης για την θεραπευτικη αντιμετωπιση του ασθματος, copd, αλλεργικης ρινιτιδας, αλλεργικης επιπεφυκιτιδας, ατοπικης δερματιτιδας, καρκινου, ηπατιτιδας β, ηπατιτιδας c, hiv, hpv, βακτηριακων λοιμωξεων και δερματωσης | |
| TW200526658A (en) | Heterocyclic inhibitors of MEK and methods of use thereof | |
| NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
| ES2422557T3 (es) | Compuestos y composiciones como moduladores de la ruta Hedgehog | |
| CY1114803T1 (el) | Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης | |
| MY144659A (en) | 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors | |
| MX2019013260A (es) | Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas. | |
| CL2008001301A1 (es) | Compuestos derivados de heterociclos de nitrogeno; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una condicion inflamatoria o alergica, tal como una enfermedad inflamatoria u obstructiva de las vias respiratorias mediada por el bloqueo del canal de sodio epitelial. | |
| HN2001000037A (es) | Derivados de eteres de pirazol como agentes antiinflamatorios/analgesicos | |
| EA200601654A1 (ru) | Ингибиторы интегразы вич | |
| CY1112311T1 (el) | Ενωσεις πυραζολινης ως ανταγωνιστες υποδοχεα αλατοκορτικοειδους | |
| NO20075111L (no) | Farmasoytisk sammensetning | |
| MY140235A (en) | New benzimidazole derivatives | |
| SE0302546D0 (sv) | New compounds | |
| WO2007057221A3 (en) | Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases | |
| UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| SE0401655D0 (sv) | New compounds | |
| ITMI20031291A0 (it) | Uso di acido ialuronico per la preparazione di composizioni per il trattamento di afte del cavo orale | |
| DK1412332T3 (da) | Quinolinderivater og anvendelse deraf som antitumormidler | |
| AR078486A1 (es) | Derivados de 3,5-diciano-4-(1h-indazol-5-il)-2,6-dimetil-1,4-dihidropiridina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades mediadas por receptores de quinasas c-met, en particular cancer y otros trastornos proliferativos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |